SCHEMBL11292528

SCHEMBL11292528

NS(=O)(=O)c1cccc(Nc2ncc3c(n2)-c2cc(-c4ccccc4OC(F)(F)F)sc2CC3)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IKBKB O14920 4/20 0.49
CDK1 P06493 8/20 0.48
CDK2 P24941 8/20 0.48
CCNT1 O60563 7/20 0.48
CCNB1 P14635 7/20 0.48
CDK9 P50750 7/20 0.48
CCNA2 P20248 5/20 0.48
CCNE1 P24864 4/20 0.48
CDK5 Q00535 4/20 0.48
CDK5R1 Q15078 3/20 0.48
CCND3 P30281 1/20 0.48
FLT3 P36888 1/20 0.48
CDK6 Q00534 1/20 0.48
CDK7 P50613 4/20 0.43
CCNH P51946 4/20 0.43
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA9 Q16790 1/20 0.42
CCNB2 O95067 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11294908 0.90 BMPR2 (0.51) IKBKBCDK1CDK2CCNT1CCNB1
SCHEMBL11297606 0.86 IKBKB (0.54) IKBKBCDK1CDK2CCNT1CCNB1
SCHEMBL11294889 0.85 IKBKB (0.53) IKBKBCDK1CDK2CCNT1CCNB1
SCHEMBL11297560 0.85 IKBKB (0.49) IKBKBCDK1CDK2CCNT1CCNB1
SCHEMBL1037588 0.85 CDK2 (0.56) IKBKBCDK1CDK2CCNT1CCNB1
SCHEMBL11297574 0.84 IKBKB (0.51) IKBKBCDK1CDK2CCNT1CCNB1
SCHEMBL11294971 0.83 IKBKB (0.51) IKBKBCDK1CDK2CCNT1CCNB1
SCHEMBL11294087 0.82 CCNT1 (0.52) IKBKBCDK1CDK2CCNT1CCNB1
SCHEMBL13591728 0.81 CCNT1 (0.52) IKBKBCDK1CDK2CCNT1CCNB1
SCHEMBL11294165 0.81 CDK2 (0.52) IKBKBCDK1CDK2CCNT1CCNB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8288400-B2 Compositions useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-10-16 US disclosed
US-8288400-B2 Compositions useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-10-16 US disclosed
US-20120183577-A1 COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-07-19 US disclosed
US-20120183577-A1 COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-07-19 US disclosed
US-8017619-B2 Compositions useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-09-13 US disclosed
US-8017619-B2 Compositions useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-09-13 US disclosed
US-20100280026-A1 COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-11-04 US disclosed
US-20100280026-A1 COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-11-04 US disclosed
US-7700609-B2 Compositions useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-04-20 US disclosed
US-7700609-B2 Compositions useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-04-20 US disclosed
EP-1692140-B1 COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMA (US) 2009-12-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100280026-A1 COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES MAP3K20, MAP3K1, MAP3K6 IKBKB 540/4885CDK1 73/4885CDK2 65/4885
US-20120183577-A1 COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES MAP3K20, MAP3K1, MAP3K6 IKBKB 540/4885CDK1 73/4885CDK2 65/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.